Glenmark Pharmaceuticals Ltd (GLENMARK) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Glenmark Pharmaceuticals reported consolidated revenue from operations of INR 32,562 million in Q4 FY25, a 6.3% YoY growth.
- The company achieved leadership positions in India, ranking second in dermatology and third in the cardiac segment.
- Europe business showed strong performance with close to 18% growth for the full year FY25, driven by RYALTRIS sales in 45+ markets.
- WINLEVI received U.K. MHRA approval in Q4 FY25.
- IGI presented positive Phase I data for ISB 2001 at the ASH conference.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.